# The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy

> **NCT04136366** · PHASE3 · COMPLETED · sponsor: **Aldeyra Therapeutics, Inc.** · enrollment: 106 (actual)

## Conditions studied

- Proliferative Vitreoretinopathy

## Interventions

- **DRUG:** ADX-2191 (intravitreal methotrexate 0.8%)
- **OTHER:** Standard surgical care procedure

## Key facts

- **NCT ID:** NCT04136366
- **Lead sponsor:** Aldeyra Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-15
- **Primary completion:** 2022-06-14
- **Final completion:** 2022-06-14
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04136366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04136366, "The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04136366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*